• Educational resources
  • Events
  • Expert Panel
No matches
  • Cookie policy
  • Privacy policy
  • About us
  • Join ADVENT
  • Contact us

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 - 4.0 - 10/2025

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: South KoreaChange country/region
Dermatology

ADVENT at San Diego, 2024

Two educational symposia at San Diego, 2024, explore the role of type 2 inflammation and the related manifestations in atopic dermatitis, prurigo nodularis, and chronic spontaneous urticaria.
Coverpage
Past event
8March2024
Location
San Diego United States

Symposium Details

March 8

The Benefits of Early Intervention In AD: More Than Skin Deep

Drs. Eichenfield, Simpson, and Abuabara educate on the importance of treating AD beyond the skin by altering the treatment approach to fit the individual patient, thereby reducing long-term patient burden.

March 8

A Tale of Two Itches: Bridging the Gap With Type 2 Inflammation in PN and CSU

Drs. Elmariah, Kim, and Metz explore the latest research on neuro-immune mechanisms driving chronic itch and inflammation in PN and CSU.

Learning objectives

  • Present new data on the systemic burden of underlying type 2 inflammation in AD within and beyond the skin across age groups
  • Discuss the cumulative life impact of uncontrolled AD and the importance of early intervention and disease control across age groups
  • Relate perspectives on the management of moderate-to-severe AD and the potential for disease modification
  • Understand the shared underlying pathomechanism manifesting in chronic signs and symptoms of PN and CSU
  • Recall the latest research on itch pathophysiology and the neuro-immune mechanisms driving the unique disease characteristics of PN and CSU

Location

San Diego United States
Tags
symposiumcoexisting diseasesdisease progressionexpert insightsmultiple disease dimensionstype 2 inflammation
MAT-GLB-2405198 - 2.0 - 09/2024 and MAT-US-2407787 v1.0 - P Exp. Date: 11/24/2025